Entropy Technologies LP Sells 287 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Entropy Technologies LP cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,829 shares of the biopharmaceutical company’s stock after selling 287 shares during the period. Entropy Technologies LP’s holdings in Intra-Cellular Therapies were worth $570,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares in the last quarter. Barclays PLC increased its position in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC increased its position in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after buying an additional 8,440 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after buying an additional 109,892 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after buying an additional 18,865 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ITCI shares. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. JPMorgan Chase & Co. increased their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Finally, Piper Sandler restated a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $127.56 on Wednesday. The stock has a market capitalization of $13.56 billion, a price-to-earnings ratio of -146.62 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 1 year low of $62.78 and a 1 year high of $128.00. The business’s 50 day simple moving average is $102.37 and its 200-day simple moving average is $86.66.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.60% of the stock is owned by insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.